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Edited by Lukas HuberAbstract The discrimination of cancer patients (including
subtypes) based on gene expression data is a critical problem
with clinical ramiﬁcations. Central to solving this problem is the
issue of how to extract the most relevant genes from the several
thousand genes on a typical microarray. Here, we propose a
methodology that can eﬀectively select an informative subset of
genes and classify the subtypes (or patients) of disease using the
selected genes. We employ a kernel machine, kernel Fisher
discriminant analysis (KFDA), for discrimination and use the
derivatives of the kernel function to perform gene selection. Using
a modiﬁed form of KFDA in the minimum squared error (MSE)
sense and the gradients of the kernel functions, we construct an
eﬀective gene selection criterion. We assess the performance of
the proposed methodology by applying it to three gene expression
datasets: leukemia dataset, breast cancer dataset and colon
cancer dataset. Using a few informative genes, the proposed
method accurately and reliably classiﬁed cancer subtypes (or
patients). Also, through a comparison study, we verify the
reliability of the gene selection and discrimination results.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The development of microarray technology, which enables
simultaneous monitoring of several thousand genes, has revo-
lutionized biological and medical research [1–6]. Microarray
data can be used to gain molecular-level insight into phenom-
ena in the human body such as the mechanism of cancer pro-
gression. However, appropriate data analysis techniques are
needed if we are to extract useful information from such large-
scale gene expression measurements. For example, unsuper-
vised learning methods have been developed for exploratory
subtype discovery of cancer, and supervised methods can be
used to ﬁnd cancer-speciﬁc genes that may be candidates for
drug targeting, to develop a diagnostic system for cancer clas-
siﬁcation, and so on. However, the high dimensionality of mi-* Corresponding author. Fax: +82-54-279-3499.
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dimensionality and singularity problems in matrix computa-
tions, making data analysis diﬃcult [7–10]. Furthermore, even
if it were possible to handle such huge data sets, the problem
remains of extracting valuable information from data on
thousands of genes. Therefore, there is a pressing need for
techniques capable of selecting the subset of genes relevant to a
particular problem from among the entire set of microarray
data. Recently, the issue of gene selection has become a central
challenge in the ﬁeld of microarray data analysis and has been
the subject of numerous studies [11–15]. Gene selection meth-
ods generally fall into one of the two categories: ﬁlter and
wrapper approaches. Filter methods rank genes according to
some pre-deﬁned criterion; for example, statistical tests such as
the T -test, F -test, andWilcoxon’s ranksum test are typical ﬁlter
techniques. These techniques have been widely used because
they are easy to understand and implement [11,16,17]. The
wrapper approach, in contrast, is more complex because it re-
quires a trained learning machine that can evaluate the rele-
vance of a selected subset of genes. The wrapper approach ﬁnds
a subset of genes and estimates its relevance using a machine
like classiﬁer. According to a criterion such as a cross-valida-
tion error rate, the wrapper updates the subset of genes itera-
tively. Support vector machine (SVM)-RFE [13] is a good
example of a wrapper method for gene selection. It is generally
accepted that wrapper methods are usually superior to ﬁlter
methods because they can consider inter-correlation of indi-
vidual variables (genes) in a multivariate manner and, more-
over, they can determine the optimal number of variables for a
particular machine [9,18].
In the present study, we propose a gene selection procedure
for classiﬁcation that uses a kernel Fisher discriminant analysis
(KFDA) which showed outstanding performance [19] as the
wrapper and a criterion for the machine. Previously, we sug-
gested a classiﬁcation and gene selection method that uses
KFDA [15]; however, it may be regarded as a compromise
between the ﬁlter and wrapper approaches. In this work, we
aimed to develop a superior method that would be purely based
on the wrapper approach, and that would therefore have all of
the advantages inherent to that approach. Kernel machines
have been used in classiﬁcation including gene selection. They
have the advantage that they work well regardless of the data
dimension (i.e., the number of genes) and hence are well suited
to the analysis of high-dimensional data. However, previous
applications of kernel machines and research into variableation of European Biochemical Societies.
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[13,20]. We use KFDA as a wrapper because it not only has the
aforementioned advantages of kernel machine but also is sim-
pler than SVM because of not solving a constrained optimi-
zation problem. Here, we develop a criterion for gene selection
using a KFDA classiﬁer and test the performance of the pro-
posed methodology by applying it to three microarray datasets.
In the next section, we present a brief description of the
KFDA algorithm and a minimum squared error (MSE)-based
framework for KFDA. We deﬁne a new gene selection crite-
rion based on the existing formalism of KMSE framework for
KFDA and the gradient method proposed by Rak-
otomamonjy [21]. In addition, we improve the robustness of
the criterion by using ranking information based on the ex-
pression values of each gene.2. Materials and methods
Note that KFDA is a non-linear classiﬁer that can outperform when
the linear methods fail because of the non-linear properties in the data
structure or sample distributions. Here, we described the algorithm of
KFDA brieﬂy. Further detailed information about KFDA (e.g., ad-
vantages and disadvantages) can be found in Mika et al. [19].
2.1. MSE approach in kernel Fisher discriminant analysis
KFDA was originally suggested by Mika et al. [19]. The derivation
of KFDA is similar to that of conventional Fisher discriminant anal-
ysis (FDA), except that the mathematical operations are performed in
a diﬀerent space. We consider a binary classiﬁcation. Let
X ¼ fx1; x2; . . . ;xl1 ;xl1þ1;xl1þ2; . . . ; xl1þl2g be the given data matrix,
where xj 2 RN denotes the jth sample vector, l1 and l2 ðl1 þ l2 ¼ l) are
the number of samples in class 1 and 2, respectively. The complete
KFDA classiﬁer is expressed as:
f ðxÞ ¼ KTaþ b ð1Þ
where Kjk ¼ kðxj;xkÞ ¼ UðxjÞ  UðxkÞ, a is a coeﬃcient vector and b is a
bias term. Notice that UðxÞ is the implicit non-linear mapping function
used in kernel machines.
Xu et al. [22] showed that the KFDA classiﬁer can be re-written in
the MSE sense as the following set of linear equations:
KKT þ lI KU
KUð ÞT l
 
a
b
 
¼ Ky
UTy
 
ð2Þ
where j and k ¼ 1; . . . ; l;U is a column vector of l ones, l is a regu-
larization parameter, and y is a coded output. Obviously, the MSE
solution depends on the output coding schemes and there are many
possible choices of coding output [22]. We used the same output coding
as Xu et al. for binary classiﬁcation. That is,
yj ¼ l=l1 if the jth sample belongs to class 1l=l2 if the jth sample belongs to class 2

ð3Þ
In this case, the complete KFDA classiﬁer solution can be obtained
as follows:
y^ ¼ KTaþUb ð4Þ
where a ¼ ðKKT þ lI l1KUUTKTÞ1ðKy l1KUUTyÞ and
b ¼ l1ðUTy ðKUÞTaÞ.
Notice that the above solution minimizes the squared error, E, be-
tween the coded output and estimated output:
E ¼ 1
2
y

 y^
T
y

 y^

¼ 1
2
y
  KTaUbT y  KTaUb ð5Þ
The proof that the above classiﬁer is equivalent to the conventional
KFDA is provided in Xu et al. [22].
2.2. Gene selection criterion
Recently, Rakotomamonjy [21] proposed a new variable selection
method for a support vector machine (SVM) classiﬁer using a gradient
of the kernel function. This method has the advantage that, compared
to SVM-RFE [13], it is signiﬁcantly less complex computationally
because it uses derivatives of a kernel function and hence calculates theGram matrix K only once during the evaluation of the relevance of
each variable. This reduction in computational complexity facilitates
the analysis of high-dimensional data. Rakotomamonjy showed
that the derivative of the Gram matrix (K) can be directly connected
with the gradient of the weight vector in the SVM classiﬁer, and thus
that these derivates can be used to identify the most relevant variable,
that is, the variable that maximizes the variation of the squared norm
of the weight vector. Here we adopt a similar approach to develop a
new gene selection criterion for the KFDA classiﬁer. Contrary to the
previous works [13,21], the key idea of our criterion is that the variable
(gene) which has a large inﬂuence on the output error (not the weight
vector of classiﬁer) is relevant to the classiﬁcation. Since the linear set
of equations for KFDA came from the objective function in the MSE
sense, we created a criterion using the squared error. The relevance
index for the ith gene, Ri, is deﬁned as
Ri ¼ oEomi

 ¼ 12
o y KTaUb T y KTaUb 
omi

 ð6Þ
where mi is an indicative variable that represents the ith gene.
If gene i is highly relevant to the classiﬁcation, it will signiﬁcantly
aﬀect the error gradient and thus Ri will have a large value. In practice,
the relevance index Ri can be computed by the following equation:
Ri ¼ 1
2
aT Dið
n  KÞKT þ K Dið  KÞT
o
a 2aT Dið  KÞY
þ 2aT Dið  KÞUb
 ð7Þ
where  is a component-wise product operation and Di is a sample
distance matrix for the ith gene, deﬁned as:
Di ¼
xi1  xi1ð Þ2 xi1  xi2ð Þ2    xi1  xilð Þ2
..
. ..
. . .
. ..
.
xil  xi1ð Þ2 xil  xi1ð Þ2    xil  xilð Þ2
2
64
3
75 lð  l matrixÞ ð8Þ
The detailed derivation of relevance index Ri is provided as sup-
plementary information on our website (http://home.postech.ac.kr/
~cjhjhj/supp_main.htm). The proposed method has an advantage that
it can signiﬁcantly reduce the computational load because it does not
require recalculation of the Gram matrix K and the solution of the
classiﬁer when we evaluate the sensitivity of each gene by removing it
from a certain gene set. Instead of the complex calculation of K, we
need to only compute the sample distance matrix Di of each gene
whenever a gene is removed. So far, we have developed a new gene
selection criterion for the KFDA classiﬁer based on the derivatives of
the kernel function. However, there is a problem related to the sample
distance matrix Di. Gene expression datasets typically contain nu-
merous extreme values caused by artifacts such as systematic noise in
the laboratory. These extreme values can distort the gene selection
procedure. Speciﬁcally, a gene with no distinct pattern across classes,
and thus a small value of the error gradient, joE=omij, may be assigned
an unrealistically high value of Ri if the value in the matrix Di is ex-
tremely large. To prevent this situation, we constructed the sample
distance matrix Di using the ranking information instead of the real
expression values because the ranking information provides a robust
similarity/dissimilarity measure, as shown in non-parametric statistical
methods such as the Wilcoxon’s ranksum test and Kruskal–Wallis test.
2.3. Biological data
We used three publicly available microarray datasets. The leukemia
dataset, which was produced for the classiﬁcation of acute lympho-
blastic leukemia (ALL) and acute myeloid leukemia (AML), consists
of 7129 probes and 72 samples [11]. The breast cancer dataset for the
discrimination between BRCA1 mutation and others (seven BRCA1
mutation samples and 15 BRCA2 mutation and sporadic samples) has
3226 probes and 22 samples [23]. The colon cancer dataset for the
diagnosis of cancer patients consists of 2000 probes and 62 samples (40
cancer tissues and 22 normal tissues) [1]. Note that all datasets address
binary classiﬁcation problems. The reason we only consider for the
binary classiﬁcation problem will be described in Section 4.3. Results
We used the proposed method to analyze the leukemia,
breast cancer and colon cancer datasets. We monitored the
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Fig. 1. Cross-validation results of three datasets. (a) leukemia dataset:
at the minimum test error point (indicated by dashed line), 17 genes are
used for classiﬁer (b) breast cancer dataset: 21 genes and (c) colon
cancer dataset: 20 genes.
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the KFDA classiﬁer and iteratively removed a proportion,
d ð06 d6 1Þ (in this paper, d ¼ 0:2), of the genes with the
smallest values of Ri until 100 genes remained. After the pool
of relevant genes had been reduced to 100, genes were removed
one at a time. The training and test datasets were obtained by
splitting the total dataset into two parts containing 80% and
20% of the total samples (similar to ﬁvefold cross-validation),
respectively, while ensuring that the proportion of classes was
balanced in the two sets. Considering the arbitrariness of this
partitioning, we repeated the above cross-validation procedure
100 times, as in our previous work [15]. By this approach, we
obtained the point that represents the minimum of the mean
test error (mean value of 100 test errors) and indicates the
optimal number of genes, m (i.e., the number that produces the
minimum error). Once the minimum error point was obtained,
we identiﬁed the m genes that were most frequently used
during 100 cross-validations at that point. For the KFDA
classiﬁer, it is necessary to determine the parameters for the
kernel function and regularization of inverse operation. The
choice of optimal parameters for kernel machines has been
extensively researched in the ﬁeld of machine learning. Various
methods (e.g., L-curve and generalized cross-validation) have
been suggested [24,25], but a detailed discussion of these
methods is beyond the scope of the present study. In the
present work, through cross-validation, we empirically deter-
mined the values of r of the kernel function and l, the
regularization parameter that produced the smallest cross-
validation error. This approach yielded values of r which
equals ﬁve times the number of genes used in the classiﬁer at
each repetition, and l equals unity.
3.1. Gene selection and cross-validation results
The leukemia dataset consists of training and test sets
comprising 38 and 34 samples, respectively. In this study, we
combined these two datasets into a single set of 72 samples;
thus, about 58 randomly selected samples were used for
training in each cross-validation step. The cross-validation
result is illustrated in Fig. 1(a). Note that the error values do
not represent a misclassiﬁcation error rate but rather the root
mean squared error between Y and Y^. From Fig. 1(a), we
recognize that the optimal number of genes, which produces
the minimum test error, is 17. As stated before, we can obtain
an optimal subset of genes by ﬁnding 17 genes that are most
frequently used over 100 cross-validations at the minimum
error point. In fact, the selected genes are not always used
together during the cross-validations and thus it is hard to
evaluate the misclassiﬁcation rate within the gene selection
procedure. Therefore, we regard the selected gene subset as an
independent dataset and verify the performance of it in the
context of classiﬁcation. After the identiﬁcation of 17 genes,
we newly make a KFDA classiﬁer and evaluate the classiﬁ-
cation ability using leave-one-out cross-validation (LOOCV).
Such a validation scheme has been already used in the previous
work [26]. The assignment of sample to the corresponding
class is achieved by logistic regression [27]. Our selected genes
for the leukemia dataset produce one misclassiﬁcation. For
breast cancer dataset, the cross-validation result for the gene
selection is depicted in Fig. 1(b). Following an approach
similar to that used for the leukemia dataset, we extract 21
genes that achieve the minimum CV test error. In the valida-
tion procedure (LOOCV-classiﬁcation), the selected genesproduce no misclassiﬁcation. The cross-validation result for
the colon cancer dataset is illustrated in Fig. 1(c). We identiﬁed
20 genes to discern cancer tissues from normal ones. The se-
lected subset of genes produced six misclassiﬁcations during
LOOCV procedure.
3.2. Comparison study
To evaluate the performance of the proposed gene selection
and classiﬁcation method, we compared our method with
previously developed methods. Although it is somewhat diﬃ-
cult to directly compare these methods because they each use a
diﬀerent criterion, we performed a comparison study by
96 J.-H. Cho et al. / FEBS Letters 571 (2004) 93–98reproducing other methods. Recent studies related to leukemia
(Guyon et al. [13]), breast cancer (Lee et al. [26]), colon cancer
(Li et al. [14]) and our previous work (Cho et al. [15]) were
chosen as targets for comparison. In studies using the same
leukemia dataset as that used here, Guyon et al. extracted four
genes and Cho et al. six genes for subtype classiﬁcation. First,
we constructed a support vector classiﬁer with exactly the same
conditions as those described by Guyon et al. for their gene
subset. Since Guyon et al. [15] found some informative genes
using 38 training samples, we newly selected gene subsets and
constructed KFDA classiﬁers by applying our previous
method and the proposed one to the 38 training samples. Due
to the change of training dataset, the selected genes are slightly
diﬀerent from the ones conﬁgured in the previous work and
Section 3.1. Note that the classiﬁer used in our previous re-
search was a conventional KFDA algorithm; thus, it is con-
ceptually diﬀerent from the classiﬁer proposed in the present
work, which is modiﬁed in the MSE sense. For comparison,
with respect to each method, we obtained the score values of
34 test samples and the estimated probabilities (i.e., posterior
probabilities) computed by logistic regression.
The breast cancer dataset was previously analyzed by Lee
et al. [26] using Bayesian approach. They demonstrated the
validity of their subset of genes by LOOCV after the comple-
tion of gene selection procedure. Therefore, we merely com-
pared our LOOCV result with theirs. For our previous
method, a gene subset is selected using all samples and the
posterior probabilities are obtained by LOOCV and logistic
regression. Although this validation, in fact, is not appropriate
since information of the ‘‘left out’’ feature in the LOOCV has
already been used to select the optimal number of genes [28],
we used it only for comparison.
For the colon cancer dataset, Li et al. [14] reported the av-
erage performance over 100 random partitions into 50 training
and 12 test samples. We exactly followed their validation
procedure and obtained average performances of our previous
method and the proposed one.
Table 1 shows the comparison results. For the leukemia
dataset, the method of Guyon et al. produced only no mis-
classiﬁcation, while the proposed method and our previous
method produced some misclassiﬁcations. At ﬁrst glance, the
lower number of misclassiﬁcations produced by the method of
Guyon et al. [29,30] would seem to suggest that this method is
superior to the other methods considered; however, it is well
known that the leukemia dataset contains at least one sampleTable 1
Comparison results
Methods Misclassiﬁcations Size of subset
(a) Leukemia dataset
Guyon et al. [13] 0 4
Cho et al. [15] 9 1
Proposed 2 17
(b) Breast cancer dataset
Lee et al. [26] 0 27, 17, 10
Cho et al. [15] 5 3
Proposed 0 21
(c) Colon cancer dataset
Li et al. [14], algorithm 1 2.04 0.14 15.13 0.31
Li et al. [14], algorithm 2 2.90 0.13 8.55 0.13
Cho et al. [15] 2.57 1.76 ) (29)
Proposed 2.15 1.2 10that is mislabeled and that may inﬂuence the error rate. Thus,
the present ﬁndings indicate that the gene subset of Guyon
et al. is slightly lacking in the ability to detect intrinsic data
faults (i.e., mislabeled samples) and will therefore produce
incorrect results due to excessive reduction of the number of
genes. Our previous method shows a poor classiﬁcation result
as shown in Table 1(a), since it ﬁnds only one gene because of
its stringent criterion (select genes always included in classiﬁer
during 100 cross-validations) [15] and thus the classiﬁer be-
comes sensitive to small perturbation in test data. Contrary to
the above two methods, the proposed method not only iden-
tiﬁes the incorrect sample but also gives estimated probabilities
of close to unity, the value for a correctly classiﬁed sample.
The present results therefore indicate that, compared to pre-
vious analysis techniques, the proposed method more eﬀec-
tively ﬁnds the intrinsic property of the data and provides a
clearer classiﬁcation result.
For the breast cancer dataset, the proposed method shows a
satisfactory classiﬁcation result as shown in Table 1(b). Like the
proposedmethod, themethod of Lee et al. also produces zero or
one misclassiﬁcation over three models that have 27, 17 and 10
genes, respectively. It is hard to address which method is supe-
rior to the other in this case, however, we can see that the pro-
posed method, which is obviously simpler than Lee et al. (using
Bayesian mixtures and Markov Chain Monte Carlo computa-
tion), keeps abreast of the highly sophisticated one.
For the colon cancer dataset, the previous research reported
average performance over 100 random partitions into 50
training and 12 test samples. Thus, we exactly follow such a
validation procedure when we implement our previous method
and the proposed one for comparison. Table 1(c) shows the
average number of misclassiﬁcations and feature set size. Our
previous method tells that the minimum average test error is
obtained when 29 genes are used for classiﬁer, however, there
is no gene which always participates in the classiﬁer con-
struction. This fact means again that our previous criterion is
too stringent. Moreover, it reﬂects that the ﬁlter approach is
inappropriate for analyzing the colon cancer dataset, since
there are few genes that consistently appear to be relevant
according to the variation of training dataset. Considering the
classiﬁcation ability and the size of subset, the proposed
method can bear comparison with the two algorithms of pre-
vious work [14].
3.3. Biological analysis of the selected genes
Many studies have been carried out on the leukemia dataset
considered here [11–13,31,32] and most of the genes we found
are part of previously chosen ones. We did, however, ﬁnd an
interesting gene, nucleoside-diphosphate kinase (NM23-H4,
Y07604) which had been selected in our previous work [12].
Based on Arthur and Bloomﬁeld [33], other researches [34,35]
and the location of NM23-H4 (16p13), we carefully supposed
that it might be a strong candidate for the AML diagnostic
marker. For breast cancer dataset, we found some genes,
keratin 8 (IMAGE ID: 897781) and transducer of ERBB2, 1
(IMAGE ID: 823940), of which the importance had been al-
ready revealed in Lee et al. [26]. Based on the fact that more
than 80% of the genes selected in the present work are the same
as those selected in the work of Hedenfalk et al. [23] and Lee
et al. [26], we can see that our method reliably extracts infor-
mative genes in consistent with the previous researches. From
the gene selection result of colon cancer dataset, we found
J.-H. Cho et al. / FEBS Letters 571 (2004) 93–98 97vascular endothelial growth factor (VEGF, IMAGE ID:
47326). Evidence from preclinical and clinical studies indicates
that vascular endothelial growth factor (VEGF) is the pre-
dominant angiogenic factor in human colorectal cancer and is
associated with the formation of metastases and poor prog-
nosis [36]. Although it is clinically important and the univar-
iate expression pattern of it is discriminative, it has not been
selected as a relevant gene in previous researches [13,14]. The
list and heat map of the selected subsets are available on our
website (http://home.postech.ac.kr/~cjhjhj/supp_main.htm).4. Discussion
In this paper, we have proposed a gene selection and clas-
siﬁcation method that utilizes a KFDA classiﬁer and the de-
rivative of the kernel function. We used a MSE framework of
KFDA and constructed a gene selection criterion based on
that MSE scheme. Since the MSE framework of KFDA can be
regarded as a regression of typical KFDA scores to the coded
output, and we focus on the error, our method can produce
discriminative scores that are pushed away to ﬁt the class-
indicative y. Most previous studies of gene selection and subtype
classiﬁcation have adopted a criterion based on misclassiﬁca-
tion rates, with little consideration given to the reliability of
classiﬁcation, i.e., the extent to which scores (or posterior
probabilities) are separated between classes. It should be borne
in mind, however, that, even if a method extracts a small
subset of genes without any misclassiﬁcation, its outputs may
lie in the marginal region. Moreover, it is possible that the
small subset of selected genes will contain no genes of bio-
logical (clinical) importance because the gene selection process
is a purely data-driven procedure that does not take into ac-
count prior biological knowledge. In fact, the number of genes
selected by the proposed method is larger than previous ones,
but it provided more accurate and reliable classiﬁcation re-
sults. In addition, the proposed method identiﬁed some inter-
esting genes unnoticed in previous studies.
The characteristics of our method can be adjusted through
the selection of the output coding scheme [22]. If the objective
of gene selection is to drastically reduce the number of genes,
for example in a commercial diagnosis system, we can achieve
this by basing the criterion (and output coding) on the mis-
classiﬁcation rate. On the other hand, if the objective is to
support further biological and medical research by selecting a
subset of genes that has considerable relevance, we could use
the error between the outputs to ensure that possible candi-
dates are not missed.
In this paper, we have considered a binary classiﬁcation
problem only. Practically, we have more chance to encounter
multiple classiﬁcation problems and thus it is necessary to
extend such a method to the multi-class case. However, it is
diﬃcult to obtain a general and non-trivial solution of multiple
discriminant analysis (MDA) without solving an eigenvalue
problem. To use the proposed gene selection criterion, we need
an objective function (to be diﬀerentiated, E in our study)
which should be directly connected with raw data, i.e., xi,
however we cannot trace the relationship with the raw data
from eigenvectors. The extension of our method into MDA
solution is in progress and will be our next research topic.
The ultimate goal of this work is to identify a set of candi-
date genes that are worthy of analysis for purposes such aselucidating the mechanism of a disease, constructing a diag-
nosis system, and developing drugs. The beneﬁts of employing
the present method to study a disease would be enhanced by
using it in conjunction with biological (clinical) experiments
related to the disease.
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